Incyte has outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.

Amini: As a radiation oncologist, I do play a larger role than I feel we used to as our patients are living longer and cure rates are improving. We are no longer just seeing the short or subacute ...